-Atossa Therapeutics Inc (ATOS) stock is trading at $4.76 as of 10:00 AM on Friday, Jun 4, a rise of $0.32, or 7.09% from the previous closing price of $4.44. The stock has traded between $4.55 and $4.92 so far today. Volume today is light. So far 2,739,675 shares have traded compared to average volume of 13,614,422 shares.
-Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in the US. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
-Prognosticator Edward Woo lifted said price target on Atossa to an even $8 per share from the previous $7.75. The new level is slightly more than twice the most recent closing price of the clinical-stage biotech. Almost needless to say, Woo has a buy rating on the stock; this remained unchanged with the price target raise.
-Atossa's most promising pipeline drug is Endoxifen, an oral treatment for breast cancer. Recently, it has also been developing a pair of medications for COVID-19. Since breast cancer is a particularly devastating and relatively widespread ailment, the company has great upside potential if Endoxifen tests well.
-Woo has been very bullish on Atossa from the get-go. He initiated coverage on the stock with a buy recommendation last September. Slapping a $7 per-share price target on it at the time, he wrote that "this valuation appropriately balances out the company's high risks with the company's high growth prospects and large upside opportunities."
-Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in the US. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
-Prognosticator Edward Woo lifted said price target on Atossa to an even $8 per share from the previous $7.75. The new level is slightly more than twice the most recent closing price of the clinical-stage biotech. Almost needless to say, Woo has a buy rating on the stock; this remained unchanged with the price target raise.
-Atossa's most promising pipeline drug is Endoxifen, an oral treatment for breast cancer. Recently, it has also been developing a pair of medications for COVID-19. Since breast cancer is a particularly devastating and relatively widespread ailment, the company has great upside potential if Endoxifen tests well.
-Woo has been very bullish on Atossa from the get-go. He initiated coverage on the stock with a buy recommendation last September. Slapping a $7 per-share price target on it at the time, he wrote that "this valuation appropriately balances out the company's high risks with the company's high growth prospects and large upside opportunities."
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.